Literature DB >> 23607977

Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab.

Shaun Ittiara1, Michael P Blair, Michael J Shapiro, Steven J Lichtenstein.   

Abstract

A 25-week postmenstrual age premature infant was treated with bilateral intravitreal bevacizumab for retinopathy of prematurity at 35 weeks' PMA. Postinjection, the retinal vessels progressed anteriorly within the retina. The patient presented 1 year after injection with bilateral exudative retinal detachments. The right eye was treated with intravitreal bevacizumab, laser ablation, and scleral buckling, resulting in resolution of the exudation and detachment. The left eye was treated with vitrectomy and lensectomy, but persistent exudation and detachment remained. This case demonstrates the rare complication of exudative retinal detachment in the setting of retinopathy of prematurity, which may become more common with increasing use of bevacizumab. Importantly, it also demonstrates the need not only for frequent examination after bevacizumab injection for retinopathy of prematurity but long-term follow-up as well, until either the retina is fully vascularized or peripheral ablation is performed.
Copyright © 2013 American Association for Pediatric Ophthalmology and Strabismus. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23607977     DOI: 10.1016/j.jaapos.2013.01.004

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  20 in total

Review 1.  Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity.

Authors:  Kay D Beharry; Gloria B Valencia; Douglas R Lazzaro; Jacob V Aranda
Journal:  Semin Perinatol       Date:  2016-01-29       Impact factor: 3.300

2.  Intravitreal injection of bevacizumab for retinopathy of prematurity.

Authors:  Kazuki Kuniyoshi; Koji Sugioka; Hiroyuki Sakuramoto; Shunji Kusaka; Norihisa Wada; Yoshikazu Shimomura
Journal:  Jpn J Ophthalmol       Date:  2014-02-26       Impact factor: 2.447

3.  Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.

Authors:  Helen A Mintz-Hittner; Megan M Geloneck; Alice Z Chuang
Journal:  Ophthalmology       Date:  2016-05-27       Impact factor: 12.079

4.  Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up.

Authors:  M Isaac; N Tehrani; K Mireskandari
Journal:  Eye (Lond)       Date:  2016-02-12       Impact factor: 3.775

Review 5.  [Review of clinical trials in retinopathy of prematurity : Current state and future perspectives].

Authors:  Andreas Stahl
Journal:  Ophthalmologe       Date:  2018-06       Impact factor: 1.059

6.  Long-term retinal vasculature abnormalities following intravitreal bevacizumab for retinopathy of prematurity.

Authors:  Amir Sternfeld; Safa Rahmani; Jennifer L Rossen; David L Zhang; Yuping D Li; Victor L Quan; Russell Huang; Hawke H Yoon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-12-01       Impact factor: 3.117

7.  Angiographic findings in cases with a history of severe retinopathy of prematurity treated with anti-VEGFs: Follow-up to age 6 years.

Authors:  Hande Celiker; Ozlem Sahin
Journal:  Int Ophthalmol       Date:  2021-11-02       Impact factor: 2.031

8.  Targeting Müller cell-derived VEGF164 to reduce intravitreal neovascularization in the rat model of retinopathy of prematurity.

Authors:  Yanchao Jiang; Haibo Wang; David Culp; Zhihong Yang; Lori Fotheringham; John Flannery; Scott Hammond; Tal Kafri; M Elizabeth Hartnett
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-10       Impact factor: 4.799

9.  A review of treatment for retinopathy of prematurity.

Authors:  Eric D Hansen; M Elizabeth Hartnett
Journal:  Expert Rev Ophthalmol       Date:  2019-03-29

10.  The results of intravitreal bevacizumab monotherapy for treating aggressive posterior retinopathy of prematurity and Type 1 retinopathy of prematurity.

Authors:  Ayşegül Çömez; Yalçın Karaküçük; Mehmet Cüneyt Özmen; Pelin Çelemler; Oğuzhan Saygılı
Journal:  Eye (Lond)       Date:  2021-01-29       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.